Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.79 |
| ▸ | LMNA | P02545 | 1/20 | 0.79 |
| ▸ | APP | P05067 | 5/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.69 |
| ▸ | HPGD | P15428 | 3/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.69 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.67 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.67 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.67 |
| ▸ | PDE4A | P27815 | 1/20 | 0.67 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.67 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.67 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | GSK3B | P49841 | 1/20 | 0.65 |
| ▸ | MMP1 | P03956 | 3/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1609268 | 1.00 | KDM4E (0.79) | KDM4ELMNAAPPALDH1A1HPGD | |
| SCHEMBL1608804 | 0.95 | KDM4E (0.79) | KDM4ELMNAAPPALDH1A1HPGD | |
| SCHEMBL1608802 | 0.95 | KDM4E (0.79) | KDM4ELMNAAPPALDH1A1HPGD | |
| SCHEMBL27833553 | 0.92 | KDM4E (0.87) | KDM4ELMNAAPPALDH1A1HPGD | |
| SCHEMBL5848040 | 0.92 | KDM4E (0.87) | KDM4ELMNAAPPALDH1A1HPGD | |
| SCHEMBL5848038 | 0.92 | KDM4E (0.87) | KDM4ELMNAAPPALDH1A1HPGD | |
| SCHEMBL8887866 | 0.91 | KDM4E (0.67) | KDM4ELMNAAPPALDH1A1HPGD | |
| SCHEMBL8887859 | 0.91 | KDM4E (0.67) | KDM4ELMNAAPPALDH1A1HPGD | |
| SCHEMBL31420052 | 0.89 | NPC1 (0.70) | KDM4ELMNAAPPALDH1A1HPGD | |
| SCHEMBL6034563 | 0.89 | KDM4E (0.78) | KDM4ELMNAAPPALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190111044-A1 | 2-PHENETHENYLTETRAHYDRO ISOQUINOLINES USEFUL AS ANTI-HIV COMPOUNDS | Prosetta Antiviral, Inc. | 2019-04-18 | — | — | US | disclosed |
| US-10195189-B2 | 2-phenethenyltetrahydro isoquinolines useful as anti-HIV compounds | Prosetta Antiviral, Inc. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20170368051-A1 | 2-PHENETHENYLTETRAHYDRO ISOQUINOLINES USEFUL AS ANTI-HIV COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-28 | — | — | US | disclosed |
| US-9518022-B2 | Anti-HIV compounds | PROSETTA ANTIVIRAL INC. (US) | 2016-12-13 | — | — | US | disclosed |
| WO-2016100391-A1 | 2-PHENETHENYLTETRAHYDRO ISOQUINOLINES USEFUL AS ANTI-HIV COMPOUNDS | Prosetta Antiviral, Inc. (US) | 2016-06-23 | — | — | WO | disclosed |
| US-20160168100-A1 | ANTI-HIV COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-16 | — | — | US | disclosed |
| US-8318785-B2 | Pharmaceutical compounds | ORION CORPORATION (FI) | 2012-11-27 | — | — | US | disclosed |
| US-20110086852-A2 | PHARMACEUTICAL COMPOUNDS | ORION CORPORATION (FI) | 2011-04-14 | — | — | US | disclosed |
| EP-1910325-B1 | NEW PHARMACEUTICAL COMPOUNDS | ORION CORP (FI) | 2010-10-06 | — | — | EP | disclosed |
| US-20090209532-A1 | PHARMACEUTICAL COMPOUNDS | ORION CORPORATION (FI) | 2009-08-20 | — | — | US | disclosed |
| EP-1910325-A2 | NEW PHARMACEUTICAL COMPOUNDS | ORION CORPORATION (FI) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007010085-A2 | NEW PHARMACEUTICAL COMPOUNDS | ORION CORPORATION (FI) | 2007-01-25 | — | — | WO | disclosed |
| US-6048875-A | CARDIOVASCULAR DISORDERS; REDUCING THROMBOSIS | ADIR ET COMPAGNIE (FR) | 2000-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190111044-A1 | 2-PHENETHENYLTETRAHYDRO ISOQUINOLINES USEFUL AS ANTI-HIV COMPOUNDS | MAVS, EIF2AK2, POLRMT | KDM4E 289/4885LMNA 3070/4885APP 2292/4885 |
| US-10195189-B2 | 2-phenethenyltetrahydro isoquinolines useful as anti-HIV compounds | MAVS, EIF2AK2, POLRMT | KDM4E 289/4885LMNA 3070/4885APP 2292/4885 |
| US-20160168100-A1 | ANTI-HIV COMPOUNDS | MAVS, SARS1, NFATC1 | KDM4E 448/4885LMNA 2556/4885APP 1169/4885 |
| US-20090209532-A1 | PHARMACEUTICAL COMPOUNDS | COMT, CYP2C19, UGT1A1 | KDM4E 2512/4885LMNA 3994/4885APP 1344/4885 |
| US-20170368051-A1 | 2-PHENETHENYLTETRAHYDRO ISOQUINOLINES USEFUL AS ANTI-HIV COMPOUNDS | MAVS, EIF2AK2, POLRMT | KDM4E 289/4885LMNA 3070/4885APP 2292/4885 |
| US-20110086852-A2 | PHARMACEUTICAL COMPOUNDS | COMT, CYP2C19, CYP3A4 | KDM4E 594/4885LMNA 3538/4885APP 1598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.